# Evaluation of Antibody Properties and Clinically Relevant Immunogenicity, Anaphylaxis, and Hypersensitivity Reactions in Two Phase III Trials of Tralokinumab in Severe, Uncontrolled Asthma

*Drug Safety*

Mats Carlsson,[1] Martin Braddock,[2] Yuling Li,[3] Jihong Wang,[3] Weichen Xu,[3] Nicholas White,[4] Ayman Megally,[5] Gillian Hunter,[6] Gene Colice[5]

[1]Patient Safety, Global Medicines Development, AstraZeneca, Pepparedsleden 1, Mölndal, SE-431 83, Sweden

[2]Global Medicines Development, AstraZeneca, Granta Park, Great Abington, Cambridge, CB21 6GH, United Kingdom

[3]Biopharmaceutical Development, MedImmune, One MedImmune Way, Gaithersburg, Maryland 20878, United States

[4]Clinical Pharmacology, Pharmacometrics and DMPK, MedImmune, Granta Park, Great Abington, Cambridge, CB21 6GH, United Kingdom

[5]Global Medicines Development, AstraZeneca, One MedImmune Way, Gaithersburg, Maryland 20878, United States

[6]Biometrics and Information Sciences, AstraZeneca, Granta Park, Great Abington, Cambridge, CB21 6GH, United Kingdom

**Corresponding author:** Mats Carlsson, Patient Safety, Global Medicines Development, AstraZeneca, Pepparedsleden 1, Mölndal, SE-431 83, Sweden.

Mats.Carlsson@astrazeneca.com

# Electronic Supplementary Material 6

Adverse events reported in ADA-positive participants during the treatment period of STRATOS 1 and STRATOS 2 (safety analysis set)

| STRATOS 1 | Tralo Q2W (*N* = 398) | Tralo Q4W (*N* = 404) | Placebo (*N* = 400) |
|---|---|---|---|
| Participants with any relevant AE, *n* (%) | 6 (1.5) | 6 (1.5) | 8 (2.0) |
| Most frequently reported relevant AEs (≥2 participants on tralokinumab), *n* (%) | | | |
| Injection site erythema | 3 (0.8) | 0 | 0 |
| Rhinitis allergic | 2 (0.5) | 1 (0.2) | 1 (0.3) |
| Erythema | 1 (0.3) | 1 (0.2) | 0 |
| Influenza | 1 (0.3) | 1 (0.2) | 0 |
| Injection site reaction | 1 (0.3) | 1 (0.2) | 0 |
| Upper respiratory tract infection | 1 (0.3) | 1 (0.2) | 3 (0.8) |
| STRATOS 2 | Tralo Q2W (*N* = 425) | | Placebo (*N* = 422) |
| Participants with any relevant AE, *n* (%) | 4 (0.9) | | 6 (1.4) |
| Most frequently reported relevant AEs (≥2 participants on tralokinumab), *n* (%) | | | |
| Injection site reaction | 2 (0.5) | | 0 |

*ADA* anti-drug antibody, *AE* adverse event, *Q2W* every 2 weeks, *Q4W* every 4 weeks, *tralo* tralokinumab

AEs were included with an onset date on or after the first day of treatment and up to the date of the last day of study treatment plus the dosing frequency

Participants were defined as ADA positive if they had an ADA positive blood sample at any time during the study